Mabion S.A. Asset Resilience Ratio
Mabion S.A. asset resilience ratio. Mabion S.A. (MAB) has an Asset Resilience Ratio of 0.03% as of September 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MAB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Mabion S.A. (2012–2018)
Asset resilience ratio of Mabion S.A. from 2012 to 2018. This chart shows how Mabion S.A.'s Asset Resilience Ratio has changed over time. Read MAB current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Mabion S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Mabion S.A. asset portfolio.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł23.00K | 0.03% |
| Total Liquid Assets | zł23.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Mabion S.A. maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Mabion S.A. Industry Peers by Asset Resilience Ratio
Compare Mabion S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Mabion S.A. Asset Resilience Ratio by Year (2012–2018)
Mabion S.A. asset resilience ratio by year from 2012 to 2018. The table below shows the annual Asset Resilience Ratio data for Mabion S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.07% | zł108.00K ≈ $29.72K |
zł144.72 Million ≈ $39.83 Million |
-4.62pp |
| 2014-12-31 | 4.69% | zł69.53 Million ≈ $19.14 Million |
zł1.48 Billion ≈ $407.64 Million |
-0.08pp |
| 2013-12-31 | 4.78% | zł36.06 Million ≈ $9.92 Million |
zł754.68 Million ≈ $207.70 Million |
-6.57pp |
| 2012-12-31 | 11.34% | zł449.85 Million ≈ $123.81 Million |
zł3.97 Billion ≈ $1.09 Billion |
-- |
About Mabion S.A.
Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartere… Read more